Evaluates relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, highlighting potential improvements in survival outcomes.
Relacorilant is an investigational, selective glucocorticoid receptor antagonist (SGRA) that increases tumor sensitivity to chemotherapy-induced apoptosis. In a phase II study in patients with PROC, relacorilant + nab-paclitaxel improved progression-free survival (PFS) with a trend toward improved overall survival (OS) and a comparable safety profile to nab-paclitaxel alone.
No takes yet. Share an insight, caveat, or question.
Lorusso et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: